Overview

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Syndax Pharmaceuticals
Treatments:
revumenib